Work

Use of Biosimilars to Infliximab During Pregnancy in Women with Inflammatory Bowel Disease: Results from the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes (PIANO) Study

Year: 2024

Type: article

Abstract: Introduction: We aimed to compare pregnancy outcomes of women with inflammatory bowel disease (IBD) utilizing biosimilar vs. originator infliximab (IFX). Methods: In a prospective cohort of pregnant women with IBD, we collected characteristics, medications, pregnancy outcomes, and developmental milestones. We compared outcomes by IFX biosimilar or originator use via bivariate statistics. Results: A total of 100 pregnant women on originator IFX and 20 on biosimilar IFX were included. There were no differences in pregnancy complications between groups (48% vs. 35%, p=0.29). Infant developmental milestones were comparable at 12 months. Conclusions: Biosimilar IFX is not associated with adverse pregnancy or infant outcomes.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/s8ge-xh36

Authors: Mahadevan, Uma, Long, Millie D., Beaulieu, Dawn, Abraham, Bincy, Kane, Sunanda, Zhang, Xian

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Pregnancy and Medication Impact

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Leona M. and Harry B. Helmsley Charitable Trust